secwatch.observer — SEC 8-K summary
======================================

Issuer:     Tvardi Therapeutics, Inc. (TVRD)
CIK:        0001346830
Form:       8-K
Filed at:   2025-01-21T23:59:59+00:00
Accession:  0001104659-25-004747
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.60
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cara Therapeutics files investor presentation for proposed merger with Tvardi
-----------------------------------------------------------------------------

- Furnishes investor presentation (Exhibit 99.1) for post-combination company with Tvardi, a STAT3-targeted fibrosis biopharma.
- Merger announced Dec 17, 2024; pending regulatory and shareholder approvals; S-4 filed with preliminary proxy/prospectus.
- Presentation is being shared with potential investors; no new financial terms or deal value disclosed in filing.
- Forward-looking statements reference efforts to regain Nasdaq compliance on stockholders' equity requirement.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1346830/000110465925004747/0001104659-25-004747-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1346830/000110465925004747/tm253758d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-004747

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer